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In order to detect novel glycophosphatidylinositol (GPI)-anchored platelet proteins, human platelets were incubated with PI-specific phospholipase 
C (PI-PLC) and the supernatant was analysed by PAGE and silver-staining for additional protein bands. PI-PLC treatment resulted in the 
appearance of at least two addltlonal novel GPI-hnked glycoprotems (GP), GP500 and GP175, m the supernatant. Their presence on the platelet 
plasma membrane surface was demonstrated by periodate/[‘H]borohydride surface-labelhng. Activation of platelets did not enhance the amount 
of GP500 and GP175 that could be cleaved by PI-PLC. In Triton X-l 14 phase partitioning of platelet membranes the membrane form of GP175. 
mfGPl75, was in the Triton phase while mfGP500 was found in the water phase. Neither GP500 nor GPI 75 were present m the supernatant of 
surface-labelled platelets treated with PI-PLC from 4 patients. diagnosed as having paroxysmal nocturnal haemoglobinurla (PNH), but the 
supernatant from platelets from healthy volunteers treated the same way contamed both. 
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1. INTRODUCTION 
The attachment of proteins to the cell membrane 
through a glycosylphosphatidylinositol (GPI) moiety as 
an alternative anchor has been described for a large 
number of proteins [l-3]. Such anchors can be cleaved 
by phosphatidylinositol-specific phospholipases e.g. by 
phospholipase C (PI-PLC) [4]. 
All of the proteins deficient on affected blood cells in 
paroxysmal nocturnal haemoglobinuria (PNH) are 
GPI-anchored proteins [5] and, in most cases, the disor- 
der is caused by defects in the synthesis of the anchor 
[6,7]. 
Although three known GPI-anchored proteins have 
been demonstrated on the surface of platelets as well as 
other cells [8-111 no systematic study has been carried 
out. We have analysed glycoproteins released from 
platelets by PI-PLC and have examined their presence 
on platelets from PNH patients. 
2. MATERIALS AND METHODS 
2.1. Materials 
Kodak X-OMAT film, leupeptm. Trlton X-l 14. thrombm, wheat 
germ agglutinin and prestained molecular weight standard mixture 
were from Sigma (St. Louis, MO). purified PI-PLC from Boehringer 
(Mannheim, Germany), phospholipase C (10% PI-specific activity). 
N-acetylglucosamine and N-ethylmaleimide were from Fluka (Buchs, 
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Switzerland), [‘H]NaBH, from Amersham Internatlonal (UK). Ben- 
zyloxy-carbonyl-Leu-Leu-Tyr-dlazomethyl ketone (ZLLY) [12] was 
kindly provided by Dr Elliot Shaw. Friedrlch Mlescher Institute. Basle 
and ant1 decay accelerating factor (DAF) MoAb by Dr David J. 
Anstee, South Western Reglonal Blood Transfusion Centre, Bnstol, 
UK. 
2.2 Cells 
Platelets from healthy volunteers were isolated from buffy coats, 
less than 12 h after blood collection. obtained from the Central Lab- 
oratory of the Swiss Red Cross Blood Transfusion Service. Platelets 
from four patients diagnosed as having PNH (current platelet counts 
were 11, 24, 140 and 167 x lo9 platelets/l) and from controls were 
isolated from EDTA-anticoagulated blood samples, less than 4 h after 
blood collection. The platelets were isolated by centrifugation and 
washed twice with 12 mM sodium citrate. 30 mM glucose. 120 mM 
NaCI, IO mM EDTA pH 6.5 (buffer 1) and once with 4 mM glucose, 
120 mM NaCl, 5 mM EDTA and 10 mM Tris-HCI pH 7 4. (buffer 
2) (AsJudged by light microscopy, contamination with leukocytes and 
erythrocytes were less than 1:105 and 1:lO’ platelets. respectively.) 
Human erythrocytes were isolated from buffy coats by centrlfugation 
and washed twice with buffer 1 and once with buffer 2. A crude 
preparation of peripheral blood leukocytes (about 80% leukocytes 
with platelets and erythrocytes) was obtained from buffy coats. After 
centrifugatlon at 1.000 xl: for 5 mm. the Interface containing the 
nucleated white cells was Incubated with 155 mM NH,CI, 10 mM 
KHCO,. 0.1 mM EDTA pH 7.4 on ice for 10 min. The cells were 
centrifuged and washed twice with buffer 1 and once with buffer 2 by 
centrifuging at 600 x g for 5 min. The supernatants and the top layer 
of the pellets were discarded. 
2.3. Surfuce-labelluzg by the periodutel[‘HJNaBH, method 
Washed platelets were surface-labelled by the periodate/[“H]NaBH, 
method [13] as optimized for platelets by Steiner et al. [14]. 
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activity of total, in the presence of 2 mM N-ethylmaletmtde m buffer 
2 at 37°C for 30 min. After incubation the samples were centrtfuged 
at 10,000 x g and 4°C for 10 min and the supernatants were centri- 
fuged again at 100,000 x g and 4°C for I h. Because of the hmtted 
sample volume the last centrtfugation was omitted in the experiments 
with samples from PNH pattents and the related control samples The 
supernatants were analysed by SDS-PAGE/silver stainmg or by SDS- 
PAGElfluorography. Samples treated on the same way but without 
any PI-PLC were used as negattve controls. 
2.5. Actrvation of platelets 
For some expertments platelets (1 x 109/mI) were activated with 0.5. 
1 or 2 U/ml thrombm at 37°C for 5 mm before treatment with PI-PLC. 
2.6. Trlton X-114 phase partition 
Platelet plasma membranes were isolated [15] and Trtton X- 114 
phase separation was performed as described by Clemetson et al. [16]. 
2.7. Afjnity rhromatogruphy with wheat germ agglutmm (U’G.4) 
The water phase and the Triton phase (diluted 10 times with 20 mM 
Tris-HCI, pH 7.4) of the Triton X-l 14 phase partition experiment and 
the supernatant from PI-PLC treated and control platelets were 
loaded individually on WGA columns The bound material was eluted 
with 2.5% N-acetylglucosamme and analysed by SDS-PAGE/silver- 
staming. 
2.8 SDS-PAGE 
SDS-PAGE was performed according to Laemmh [17]. The gels 
were silver-stamed by the method of Morrissey [18] or were prepared 
for fluorography [19]. 
3. RESULTS 
In order to find novel GPI-linked platelet proteins. 
washed human platelets were incubated with PI-PLC 
and the supernatant was analysed for additional protein 
bands compared to an untreated control in a silver- 
stained gel. In preliminary experiments, the concentra- 
tion of platelets and PI-PLC, the type and concentration 
of protease inhibitor and the time of incubation were 
optimized. Since platelets incubated at 37°C release 
proteases (mostly calpains) it was necessary to add in- 
hibitors that do not affectPI- PLC activity. ZLLY, a 
specific calpain inhibitor, leupeptin and N-ethylmaleim- 
ide were examined as protease inhibitors. ZLLY was 
particularly effective at low concentrations in inhibiting 
cleavage of GPIba and GPV from the platelet mem- 
branes, however, it was only available in small amounts. 
Incubation of platelets with PI-PLC resulted in the ap- 
pearance of two protein bands, GP500 and GPl75, 
present only in the supernatant of PI-PLC treated sam- 
ple (Fig. 1, lane B) and absent in the supernatant of the 
negative control (Fig. 1. lane A). Any of the three inhib- 
itors, mentioned before, were sufficient to inhibit prote- 
olysis of GP500 and GP175. In the experiment shown 
in Fig. 1, N-ethylmaleimide was used as an effective 
inhibitor of GP500 and GP175 proteolysis although 
some cleavage of GPIb and GPV still occurred. Highly 
purified PI-PLC and a phospholipase C preparation 
containing 10% PI-specific activity of total were equally 
effective in causing GP500 and GP175 to appear in the 
supernatant. When the supernatant from PI-PLC 
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Fig. 1. Electrophoretic analysis of platelet supernatants and eluates 
from WGA column. (A) Supernatant of platelets Incubated without 
PI-PLC (B) Supernatant of platelets Incubated with PI-PLC. A and 
B were loaded on a WGA column and the bound maternal was eluted 
with GlcNAc. (C) The eluate from WGA usmg A. (D) The eluate from 
WGA using B. The samples were denatured under reducmg conditions 
and separated on a 4 5515% gradient polyacrylamtde gel that was then 
stlver-stained GPV. glycoprotem V; Cc. glycocahcm (the major prote- 
olytic fragment of GPlb). 
treated platelets was loaded on a WGA column both 
GP500 and GP175 were bound and could be eluted with 
N-acetylglucosamine showing that they are glycopro- 
teins (Fig. 1, lane D). The positions of prestained 
marker proteins correlated poorly with the positions of 
glycoproteins of known mass in the gel. When the two 
novel glycoproteins were compared to glycoproteins of 
known mass in gradient polyacrylamide gels under non- 
reducing conditions, GP500 was above the position of 
thrombospondin trimer (420 kDa [20]) and GP175 was 
just above GPIb (170 kDa [21]) so that their masses are 
about 500 kDa and 175 kDa, respectively. Comparison 
of the migration of GP500 and GP175 under nonreduc- 
ing and reducing conditions showed that both migrated 
slightly more slowly under reducing conditions (not 
shown). This indicates the presence of intramolecular 
disulphide bonds. 
In order to rule out a leukocyte or erythrocyte origin 
of these novel glycoproteins, platelets (2 x lO’“/ml), leu- 
kocytes (3 x 107/ml) and erythrocytes (3 x lox/ml) were 
incubated with PI-PLC and the supernatants were 
analysed for the presence of GP500 and GP175 by SDS- 
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Fig. 2. Fluorogram of platelet supematants. Supernatants of PI-PLC 
treated and untreated surface-labelled platelets were separated by 
SDS-PAGE and the gel was prepared for fluorography. (A) Superna- 
tant of untreated platelets. (B.C) Supernatants of PI-PLC treated 
platelets. (B) purified PI-PLC. (C) Phosphohpase C preparation with 
PI-specific activity 10% of total. In order to demonstrate GP500, 
GP175 and DAF, in the same gel. a4.5-10% gradient gel was used and 
the run was stopped only when the 81 kDa prestamed marker reached 
the bottom of the gel. Under these conditions glycoprotein V (GPV) 
and DAF were clearly separated. Cc: glycocahcm (the major prote- 
olytic fragment of GPIb). 
PAGE/silver staining. No protein band corresponding 
to GP500 visible in platelet supernatant was found in 
supernatants from leukocytes and erythrocytes while a 
weak band with an intensity about one fifth of the 
GP175 band in platelet supernatant was detected in the 
supernatant of leukocytes but not of erythrocytes. 
To show that GP500 and GP175 were on the platelet 
surface, before cleavage with the enzyme, surface-la- 
belled platelets were treated with PI-PLC and the super- 
natant was analysed by gel electrophoresis and Auorog- 
raphy. Both GP500 and GP175 were labelled (Fig. 2). 
In Fig. 2 another labelled glycoprotein is visible only in 
the PI-PLC-supernatant (lanes B and C) and absent in 
the supernatant of the negative control (lane A). This 
labelled glycoprotein was shown by Western blotting to 
be DAF, a known GPI-linked glycoprotein on platelets 
[8,9] (data not shown). 
Triton X-114 phase separation of platelet plasma 
membrane was performed and glycoproteins from the 
water phase and Triton phase were isolated by affinity 
chromatography on wheat germ agglutinin and the 
samples were analysed by SDS-PAGE/silver-staining 
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for the presence of the membrane form of GP500 and 
GP175 (mfGP500, mfGP175). Because of the hydro- 
phobic character of the GPI-anchor both glycoproteins 
were expected to be present in the Triton phase similar 
to other GPI-anchored proteins. Surprisingly, only 
mfGP175 but not mfGP500 was in the Triton phase. 
mfGP500 was predominantly in the water phase (data 
not shown). 
The amount of GP500 and GP175 that could be re- 
leased with PI-PLC from resting and activated platelets 
were compared. No difference was found in the inten- 
sity of silver stained bands of GP500 and GP175 of 
PI-PLC treated supernatants from resting compared 
with thrombin-activated platelets. Thrombin activation 
itself did not result in the release of GP500 and GP175. 
It was expected that GP500 and GP175, as other 
GPI-anchored proteins, would be absent or deficient in 
PNH. Surface-labelled platelets from 4 PNH patients 
were treated with PI-PLC and the supernatants were 
analysed by SDS-PAGE/fluorography. In all cases 
platelets from healthy volunteers were used as positive 
(PI-PLC treated) and negative (no PI-PLC) controls. 
No labelled protein band in the position of either GP500 
or GP175 could be identified in any of the 4 PNH 
patients (Fig. 3). 
4. DISCUSSION 
The proteins attached to the platelet plasma mem- 
brane by GPI-anchors described till now are: CD55 
(decay accelerating factor or DAF) a glycoprotein with 
a mass of about 70 kDa [8,9], the 20 kDa CD59 mole- 
cule (which has a large number of alternative names e.g. 
membrane inhibitor of reactive lysis or homologous re- 
striction factor 20) [lo] and C8 binding protein which 
has a mass of 50 kDa [ll]. Besides these complement 
regulatory proteins which are generally accepted to be 
GPI-linked, Dhar and Shukla [22] have reported an 
additional GPI-anchored platelet membrane glycopro- 
tein in the higher molecular weight region which they 
suggested is GPIb. However, GPIb is a transmembrane 
glycoprotein with a known transmembrane domain 
linked to the cytoskeleton and does not contain consen- 
sus sequences for GPI attachment [23]. In our experi- 
ments we could not detect any cleavage of GPIb by 
PI-PLC. It is easily cleaved to a water-soluble fragment, 
glycocalicin, by several proteases including calpain. It 
seems likely that glycocalicin released by proteases such 
as calpain was responsible for the GPIb that they re- 
ported. We also could detect glycocalicin in the super- 
natant of PI-PLC treated platelets but the same amount 
of glycocalicin was also present in the supernatant of 
platelets that were incubated without PI-PLC. In Fig. 
3 but not Fig. 2, GPIb is visible in all of the samples, 
including the supernatants. In the case of the PNH pa- 
tients and related controls the final centrifugation was 
omitted and the microvesicles, formed as a result of 
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Fig. 3. Fluorogram of surface-labelled control and PNH platelet ly- 
sates, and supernatants and pellets from surface-labelled control and 
PNH platelets. (A,B.C) PNH patient, (A) PI-PLC supernatant. (B) 
pellet after PI-PLC treatment, (C)platelet lysate. (D-H) Control, (D) 
PI-PLC supernatant, (E) pellet after PI-PLC treatment, (F) platelet 
lysate. (G.H) supernatant and pellet from untreated platelets. Samples 
from a patient and a healthy volunteer were run m 4.5-l 5% gradient 
polyacrylamtde gel and the gel was prepared for fluorography. Arrow- 
heads Indicate the positions of GP500 and GP175. 
vesiculation from the platelet membranes during the 
incubation, were not removed. The GPIb seen is thus 
from vesicles. Its intensity is the same in the PI-PLC 
treated (lane D) and untreated (lane G) supernatants of 
control platelets clearly showing that its appearance is 
not PI-PLC dependent. 
Incubation of platelets with PI-PLC resulted in the 
release of two additional GPI-linked platelet membrane 
glycoproteins. GP.500 and GP175, in the supernatant 
showing that they are anchored to the plasma mem- 
brane by a GPI-anchor. The fact that no protein band 
in the position of GP500 and only a weak band in the 
position of GP175 (in case of leukocytes) could be de- 
tected in the supernatants of PI-PLC-treated leukocytes 
and erythrocytes, with concentrations several hundred 
times higher then the leukocyte and erythrocyte con- 
tamination of platelet samples used, confirms the plate- 
let origin of these two novel glycoproteins described. 
Their location on the outer surface of the plasma mem- 
brane was further supported by surface-labelling of 
platelet samples. Fig. 2 shows that the two novel 
glycoproteins and DAF appeared simultaneously in the 
PI-PLC supernatant. Based on their sensitivity to PI- 
PLC two groups of DAF molecules can be distinguished 
on human blood cells. Only lo-15% of DAF is released 
from erythrocytes by PI-PLC compared with 6680% 
52 
from leukocytes [2]. Comparison of the amount of DAF 
in the supernatant and remaining pellet of PI-PLC 
treated platelets suggests that platelet DAF, like DAF 
on leukocytes, is readily released by PI-PLC. CD59 and 
C8 binding protein could not be directly identified 
under the conditions used here. There is a slight differ- 
ence between the PI-PLC treated and untreated super- 
natants in the expected position of these proteins (Fig. 
1, lanes A and B). Since they had already been identified 
on platelets we did not change our experimental condi- 
tions to characterise them better. 
To date at least nine GPI-anchored proteins have 
been reported to be missing from blood cells in PNH [5]. 
The variety of proteins involved and the fact that 
mRNA of DAF from PNH cells is fully expressed [6] 
clearly show that the defect is post-translational. Recent 
evidence suggests that it is caused by the defective syn- 
thesis of the GPI anchor [7]. It is difficult to connect 
expression of GP500 and GP175 with the degree of 
thrombocytopenia since 2 patients had severe throm- 
bocytopenia while 2 had platelet counts in the low nor- 
mal range. GP500 and GP175 were undetectable in all 
of them. In addition to GP500 and GP175 there are 
some other bands only visible. or stronger in PI-PLC 
supernatants from controls compared to PI-PLC super- 
natants from PNH patients (Fig. 3, lanes D and A). The 
reason is not clear but decreased vesiculation from PNH 
platelets might possibly be a contributory factor [24]. 
The result of experiments with thrombin-activated 
platelets showed that no additional GP500 and GP175 
was expressed on the cell surface during platelet activa- 
tion and the activation itself did not results in the release 
of these glycoproteins from the membrane surface. 
Despite the presence of the hydrophobic GPI-anchor. 
mfGP500 was found in the water phase after Triton 
X-l 14 phase separation of platelet plasma membrane. 
This suggests that the protein part of the molecule is 
strongly hydrophilic, perhaps due to high glycosylation, 
which outweighs the hydrophobic character of the an- 
chor. 
The biological function of these two glycoproteins, 
GP500 and GP175, is not yet known, so that the ques- 
tion whether their lack might contribute to the symp- 
toms of PNH remains open. 
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